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Background: Bruxism is a disorder of jaw-muscle activity characterised by repetitive clenching or grinding of the
teeth which results in discomfort and damage to dentition. The two clinical manifestations of the condition (sleep
and awake bruxism) are thought to have unrelated aetiologies but are palliated using similar techniques. The lack
of a definitive treatment has prompted renewed interest in biofeedback, a behaviour change method that uses
electronic detection to provide a stimulus whenever bruxism occurs. This systematic review aims to provide a
comprehensive overview of the state of research into biofeedback for bruxism; to assess the efficacy and acceptability
of biofeedback therapy in management of awake bruxism and, separately, sleep bruxism in adults; and to compare
findings between the two variants.
Methods: A systematic review of published literature examining biofeedback as an intervention directed at controlling
primary bruxism in adults. We will search electronic databases and the grey literature using a predefined search
strategy to identify randomised and non-randomised studies, technical reports and patents. Searches will not be
restricted by language or date and will be expanded through contact with authors and experts, and by following
up reference lists and citations. Two authors, working independently, will conduct screening of search results,
study selection, data extraction and quality assessment and a third will resolve any disagreements. The primary
outcomes of acceptability and effectiveness will be assessed using only randomised studies, segregated by bruxism
subtype. A meta-analysis of these data will be conducted only if pre-defined conditions for quality and heterogeneity
are met, otherwise the data will be summarized in narrative form. Data from non-randomised studies will be used
to augment a narrative synthesis of the state of technical developments and any safety-related issues. PROSPERO
registration number: CRD42013006880.
Discussion: Biofeedback is not new, but its place in the clinical management of bruxism remains unclear. New
research, and the availability of miniaturized consumer-grade devices, makes a systematic review timely to guide
treatment decisions and inform future research.
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Description of the problem
Bruxism is a repetitive jaw-muscle activity characterised
by clenching or grinding of the teeth and by bracing or
thrusting of the mandible [1]. Bruxism may be either
primary (idiopathic) or secondary [2,3]. Primary bruxism
is divided into two types that are thought to be clinically
unrelated: sleep and awake bruxism. Sleep bruxism (SB)* Correspondence: c.huckvale@imperial.ac.uk
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unless otherwise stated.is involuntary and is classified as a sleep-related movement
disorder [1]. Awake bruxism (AB), by contrast, is defined
as the awareness of jaw clenching, and appears to be
semi-voluntary [2-4]. In adults under 65, the prevalence
of SB is around 10% and declines gradually with age
[2,3,5]. AB prevalence is probably higher and, unlike SB, is
more frequently observed in females [4,5]. Secondary brux-
ism has been observed as a side effect of medication use
and in some neurological and developmental disorders. In
the future, it may be possible to further differentiate forms
of bruxism according to the underlying cause and clinical
manifestations [6].td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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that includes currently poorly defined aspects of central
nervous system function, genetic and behavioural factors
[2-4]. While AB is currently considered to be a paraf-
unctional reaction to mental or physical stress [3,4], SB
may be a pathological variant of normal physiological
activity involved in upper airway patency maintenance
and oesophageal lubrication [1,7]. Patients with SB exhibit
patterns of sleep arousal not seen in usual controls or
patients with AB [4,8,9]. However, stressors and mood also
appear to play a role in SB [4], and both conditions display
patterns of altered autonomic sympathetic activation [10]
and neurochemistry [11]. A number of other conditions
may coexist with bruxism, including temporomandibu-
lar joint disorder (TMD), orofacial pain, headaches and
sleep-disordered breathing. The causal relationships be-
tween these conditions and bruxism remains unclear
[8]. Some authors view bruxism as an underlying cause
of TMD, while others consider both bruxism and TMD
as related consequences of abnormal muscle activation.
The management of bruxism is not affected by coexist-
ing TMD.
Episodes of bruxism consist of masticatory muscle
activity during wakefulness or sleep and manifest as a
range of signs and symptoms in the orofacial region
[12]. The symptoms of AB and SB are similar and include
tooth grinding, jaw-muscle discomfort with or without
frank pain [13], temporomandibular joint tenderness,
facial pain and headache [8]. SB symptoms are usually
worst in the morning on waking and improve during
the day, while patients with AB may develop symptoms
only after waking [4]. Signs include abnormal tooth
wear, tongue indentation, increase in jaw muscle activity
(measured by electromyograph (EMG) or polysomno-
graph (PSG)), masseter muscle hypertrophy, reduction
in salivary flow, lip or cheek biting, gum recession,
limitation of ability to open the mouth, and burning
tongue [2,13,14]. The negative consequences of bruxism
include subjective impacts like stress, anxiety, tiredness
and poor sleep quality, as well as damage to teeth, which
may ultimately result in premature loss of dentition [8].
Because of the variety of symptoms and overlap with
other conditions, diagnosis of bruxism requires a careful
process of assessment that incorporates questionnaires,
history taking and examination. Objective testing is
uncommon outside research settings, but includes EMG
recording of the activity of the masticatory muscles
and PSG recording of the sleeping patient. While full
audio-video PSG recording remains the gold standard
for diagnosis of SB [1,14,15], standardized clinical diagnos-
tic criteria have also been proposed [1,15,16]. There are
no validated objective tests for the diagnosis of AB, which
relies instead on direct questions and visual observation of
patient behaviour [3].No therapy to date has been shown to effectively and
permanently cure bruxism [2,8]. Current treatment focuses
on symptom management and prevention of further com-
plications [8,17,18]. The most widely accepted management
approaches are intraoral appliances, pharmacotherapy (for
SB), and behavioural strategies [8].
Intraoral appliances (occlusal splints and anterior tooth
appliances) protect teeth from pathological wearing and
relax the masticatory muscles. The palliative effect of
intraoral appliances seems to be transient, however, and
may result in side effects that include pain and, less
commonly, altered occlusion that interferes with bite [8].
Pharmacological agents have been used to treat SB by
targeting neurochemical systems involved in orofacial
motor activity. Despite experimental use of a variety of
compounds, including benzodiazepines and other muscle
relaxants, antidepressants, anticonvulsants, dopaminergic
drugs and beta blockers [2,8], there is currently limited
evidence supporting routine application in clinical practice
[19]. Although botulin toxin may have a future role [20],
there are no widely accepted pharmacological approaches
for the management of AB [1].
Characterisation of bruxism as a parafunctional activity
rather than a muscle disorder per se has prompted interest
in the scope for cognitive and psychological interventions
that might modify the behaviour directly. Behavioural
approaches that have been attempted include patient
education, sleep hygiene, habit retraining, relaxation
techniques, meditation, hypnotherapy, autosuggestion,
psychoanalysis, cognitive behavioural therapy and bio-
feedback [8,17]. Conclusions concerning each of these
have historically been limited by the number and quality
of available studies [2,8,17].
Techniques directed specifically at pain relief include
transcutaneous electrical nerve stimulation, acupuncture
and manual massage. While potentially beneficial for the
subset of patients where pain is a major management
issue, there is a lack of robust evidence justifying clinical
use [21].
Description of the intervention
Biofeedback is a technique that provides individuals with
information about their bodily functions with the intention
of promoting changes in behaviour that result in improved
health or performance [22,23]. Electronically detected
physiological measurements are coupled with a feed-
back signal that is initiated when pre-specified criteria
are met and terminated only when the desired change
in behaviour occurs. Biofeedback aims to generate a
learned response that persists even after the technique is
discontinued [24]. Feedback can be provided in a number
of ways; for example, as visual information displayed to a
patient or as a sensory stimulus. Biofeedback has been
employed for a range of conditions including urinary
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rehabilitation after stroke [26] and in maintenance of
mobility and gait in older patients [27]. The most con-
vincing evidence of the potential efficacy of biofeedback
comes from studies examining feedback as an adjunct
to muscle exercises for the treatment of female pelvic
floor dysfunction [28].
Bruxism biofeedback typically involves a contemporary
stimulus generated in response to a detected grinding
or clenching event (Figure 1). Detection may rely on
mechanical sensors integrated into splints, EMG or
PSG analysis, with subsequent electronic analysis based
on patterns of activity meeting pre-specified criteria. The
paired feedback may be auditory, vibratory, electrical or
gustatory and, in the case of SB, can either be intended to
be waking or non-waking [29]. In wakeful patients, the
stimulus is intended to promote awareness of clenching
and prompt relaxation of the jaw muscles as well as
permit reflection on the context or patterns of thought
that might have given rise to the bruxism. The stimulus
is not intended to be noxious but to be of sufficient
magnitude to, at least initially, intrude into conscious
thought and alert the patient. For sleeping patients,
stimuli may either be intended to disrupt sleep or to
provide a non-waking stimulus that is processed in
some way by the sleeping brain. The recent finding that
conditioned learning can occur during sleep in humans
[30] suggests that biofeedback need not wake a patient
to be effective. Because biofeedback is intended to cause a
learned change in behaviour, there is the prospect of long-
term reduction or elimination of symptoms in addition to
palliating the condition by disrupting bruxism during the
period of active treatment.
A related mode of management for SB is contingent
electrical stimulation (CES), in which feedback is pro-
vided as an electrical stimulus applied to the skin, lip, orFigure 1 Schematic mode of action of biofeedback for bruxism.masticatory muscles. The possibility of local effects in-
cluding changes in biochemistry in stimulated tissues, in
addition to higher cognitive responses, sets CES apart
from other forms of bruxism biofeedback.
Adverse effects of the intervention
Adverse effects associated with biofeedback are most likely
to centre on the feedback stimulus. Frequent arousal may
lead to fatigue and, in SB, sleep disruption and consequent
daytime sleepiness [3,4]. Sleep disturbance may affect
bed partners. Some forms of biofeedback can include
sensations which may be unpleasant and intended to
cause an aversive response, for example by generating an
unpleasant taste. When the stimulus is electrical, pain may
be experienced if the magnitude is not configured appro-
priately. All adverse effects are expected to be transient
and would cease if the intervention were discontinued.
Why it is important to do this review
Interest in biofeedback management of bruxism has
recently revived. Two factors appear to be relevant.
Firstly, there remains no satisfactory definitive treatment
for bruxism on grounds of efficacy and acceptability.
Secondly, recent technical advances permit smaller and
cheaper biofeedback appliances that may now make
wider uptake feasible.
This review will complement a recent systematic re-
view which failed to find strong evidence to support
the use of biofeedback technology on SB treatment and
highlighted the confusing diversity of different forms of
biofeedback available [31]. In response to this, we will
generate a taxonomy of biofeedback types and use this
to structure our analysis. We will also include AB,
recognising the potential to compare and contrast as-
pects of intervention design and findings between the
two condition variants.
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We aim to: (1) provide a comprehensive overview of the
state of research concerning biofeedback for bruxism,
including a taxonomy of different types of biofeedback;
(2) assess the efficacy and acceptability of biofeedback
therapy in management of AB and, separately, SB in
adults; and (3) characterise shared issues concerning
the use of biofeedback for AB and SB as well as issues
specific to each.Methods/design
Review design
A systematic review combining an initial synthesis to
describe the state of research and present a taxonomy
of biofeedback types and, if appropriate, a subsequent
meta-analysis of trial evidence for the efficacy of bio-
feedback for SB and, separately, AB. If no meta-analysis
is appropriate then we will present a narrative summary
of trial results. The conduct of the review will be based
on the Cochrane Handbook for Systematic Reviews of
Interventions, Version 5.1.0 [32].Criteria for including studies in the review
Participants
We will include studies of adults aged 18 years or older
with either: a clinical diagnosis and/or ambulatory EMG/
electrocardiograph/PSG diagnosis or full PSG diagnosis
of SB; or a diagnosis of AB, identified by means of direct
questions and visual observation of patient behaviour
[3]. For SB, we will accept any diagnosis based on clinical
or research PSG criteria that are consistent with the Inter-
national Classification of Sleep Disorders Second Edition
criteria (Table 1) [15]. We will include adults with coexist-
ing diagnoses that may be related to bruxism but which
do not affect clinical management (for example, TMD).
We will exclude participants with: known neurological
and psychiatric comorbidities, secondary bruxism [33];
and/or a past history of receiving biofeedback for bruxism
or co-existing alternate therapy for bruxism because this
may affect how these patients will respond to treatment.Table 1 Clinical and polysomnographic criteria for diagnosis
Clinical criteria
The participant reports or is aware of tooth grinding or clenching
during sleep (3–5 nights per week over past 6 months) and one
or more of the following:
- Abnormal tooth wear,
- Jaw muscle discomfort, fatigue or pain, and jaw lock upon awakening,
- Masseter muscle hypertrophy evident on voluntary forceful clenching.Interventions
We will include studies that use biofeedback as an inter-
vention directed at reducing or controlling bruxism.
Qualifying interventions must pair a mechanism for
detecting bruxism (for example, EMG analysis) with a
contemporary feedback mechanism (for example, auditory
warning). We will place no restriction on the nature of
either the detection mechanism or the feedback, but
will constitute subgroups to explore the relative effect
of different types of monitoring and feedback. In particu-
lar, because the learning potential associated with CES
remains unclear, we will analyse CES studies separately
from other forms of biofeedback.
We will not include studies that use biofeedback to
warn about elevated tension in mandibular musculature,
rather than bruxing, since the mode of action of such
interventions in preventing future bruxism is unclear
and may not be the same as techniques that provide
contemporary feedback about detected bruxism [34-37].
We will consider interventions of any duration (provided
that duration is clearly defined).
Comparisons
We will include comparisons with placebo (sham bio-
feedback) and other types of intervention for bruxism
including behavioural strategies, oral appliances and
pharmacological treatments. We will also include com-
parisons between different types of biofeedback.
Outcomes
We will consider the following primary and secondary
outcomes, which are defined in respect of review
Objective 2.
Primary outcome
1a. Frequency of bruxism episodes measured with
either EMG or PSG (number of bruxing episodes
per day/night/otherwise specified time frame).
1b. Duration of bruxism episodes measured with either
EMG or PSG (number of time units per episode).of sleep bruxism
Polysomnographic criteria
Polysomnographic monitoring demonstrates both of the following:
jaw muscle activity during the sleep period and absence of
associated epileptic activity.
Polysomnographic diagnostic cut-off criteria:
- More than four bruxism episodes per hour;
- More than six bruxism bursts per episode and/or 25 bruxism bursts
per hour of sleep; and
- At least two episodes with grinding sounds.
Table 2 Generic search strategy
ID Term Description
1 brux* Search for any word with ‘brux’ as its stem.
2 *bruxism/OR
*sleep bruxism/
Search for the keywords or subject
headings ‘bruxism’ or ‘sleep bruxism’.
3 1 AND 2
Because of poorly defined and unstandardised terminology, we elected to use
a simple, sensitivity- maximising search strategy.
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2. Self-reported (or reported by sleeping partners in SB)
frequency of bruxism episodes (approximate number
of times bruxing occurs during the day/night).
3. Self-reported pain (facial pain, myofascial headache)
assessed using a validated instrument (points on
different scales for subjective assessment of pain or
questionnaires).
4. For SB only, quality or duration of sleep assessed
using a validated instrument (points on different
scales of number of hours of sleep per night).
5. Stress level, assessed using a validated instrument
(points on different scales).
6. Quality of life assessed using a validated instrument
(points on different scales).
7. Compliance with the intervention (proportion of
sessions completed as planned).
8. Nature and duration of any reported side effects.
Outcomes will be segregated by bruxism subtype. If
data are available, outcomes will be characterised at the
completion of the intervention period and, because we
are interested in the potential for long-term changes in
bruxism severity, separately at the conclusion of any
follow-up after the intervention period. We will segre-
gate outcomes based on the duration of the preceding
intervention and follow-up periods. To do this, interven-
tion periods will be divided into three groups: interventions
continuing for less than 48 hours; interventions continuing
between 48 hours and 7 days; and those continuing for
more than 7 days. Follow-up periods will be divided
into three periods: less than 3 months, between 3 and
12 months, and 12 months or longer.
By validated instrument we mean any data collection
tool that has a recognised standard form for administration
and that has been subject to evaluation to demonstrate
reliability and construct validity. We recognise that mea-
sures of pain and disruption to sleep may reflect beneficial
effects of the intervention (reduced pain), side effects
(increased or de novo pain) or both. Scoping suggests
that most research is in the form of laboratory-based
pilot studies and that defining implementation-related
outcomes like cost would be premature.
Study types
In respect of review Objective 1 we will include any study
type that provides evidence about types of biofeedback,
technical aspects of development and any safety-related
issues.
For Objective 2 we will include randomised or quasi-
randomised controlled trials with end-point comparisons.
We will also include randomised cross-over studies but
will analyse only the first time period as we expect carry-over to influence subsequent data [38]. For this objective,
we will exclude any other study design, namely case
series, observational cohorts, case–control and uncon-
trolled studies, before and after design, case reports,
editorials, systematic or other reviews and commentaries.
We will also exclude complex interventions where bio-
feedback forms only one part of treatment as the effects of
biofeedback may not be clearly isolated.
Search methods for identifying studies
The review will be based on a literature search of the elec-
tronic databases Cochrane Central Register of Controlled
Trials (CENTRAL), MEDLINE, EMBASE, PsycINFO and
Web of Knowledge (databases Web of Science®, Derwent
Innovations IndexSM and Chinese Science Citation Data-
baseSM) using a simple, sensitivity-maximising search
strategy (Table 2) tailored to each resource. We will also
search clinical trial registries and contact authors of any
pending or unpublished studies. We will search the grey
literature using OpenGrey and ProQuest Dissertations.
No language or date restrictions will be applied to the
search. However, we will only consider articles written in
a language other than English if they possess an English
abstract. Studies with such abstracts but not available in
English will be translated by a commercial translation
service. We will review the reference lists of included
articles and contact study authors for purposes of clarifica-
tion or for information on additional relevant published or
unpublished studies. Prior to publication, we will perform
an update search to identify any new citations.
Two authors (SI and DZ) will perform the search inde-
pendently and compare the results to ensure accuracy. A
third author (KH) will inspect the searches to confirm
that they have been carried out correctly. We will keep
records of the numbers of articles returned for each term
defined for the search separately, and when combined
using Boolean operators and before and after removal of
duplicates. We will use EndNote X6 (Thomas Reuters,
New York, NY USA) software for de-duplication.
Data collection
Selection of studies
After search and removal of duplicates, two authors (SI
and DZ) will scan the selected articles to identify any
with missing abstracts or titles. These will be located by
Ilovar et al. Systematic Reviews 2014, 3:42 Page 6 of 9
http://www.systematicreviewsjournal.com/content/3/1/42manually searching the source databases and/or using a
general-purpose search engine. Two authors (SI and DZ)
will then independently examine titles and abstracts to
exclude obviously irrelevant articles. Decisions from
this initial screening phase will be compared and any
discrepancies about which articles to retain resolved by
discussion. One author (DZ) will then obtain full text
copies, including translations if required, of all potentially
relevant studies. The same authors, working independently,
will then assess articles against the full inclusion criteria
(Table 3) to confirm that they should be included in the
review. Disagreements will be resolved through discussion.
If no agreement can be reached, KH will act as arbiter.
A log will be kept of all screening and full-text decisions.
Reasons for exclusion of articles at the full text stage will
be recorded for publication in the review. We will use a
PRISMA chart for showing study selection process and
reasons for exclusion.
Data extraction and management
Two authors, SI and DZ, will independently extract data
from included studies using a structured form. We plan to
extract relevant data on study (for example, design, set-
ting, country), population (for example, age, gender, type
of bruxism, co-morbidity), intervention (for example, type,
length), and outcome characteristics (for example, type
of measurements, follow-up timing). The data extraction
forms completed by each reviewer will be compared and
discrepancies followed up with reference to the original
article. We will contact authors to obtain missing orTable 3 Inclusion and exclusion criteria
Inclusion criteria
Adults 18 or older
Clinical or EMG/PSG-based diagnosis of SB or clinical diagnosis
of AB
Co-existing diagnoses not affecting clinical management of bruxism
Biofeedback as an intervention for reducing or controlling bruxism
Any valid comparison (placebo, other intervention or
biofeedback type)
Any duration
Outcomes reported at completion of active therapy and (optionally)
at completion of follow-up
Any language
Published or unpublished work
In respect of Objective 1 only:
Any study type that provides evidence about types of biofeedback,
technical aspects of design and clinical use or safety issues.
In respect of Objective 2 only:
Randomised or quasi-randomised control trials or randomised
cross-over studies
AB, awake bruxism; EMG, electromyograph; PSG, polysomnograph; SB, sleep bruxismincomplete data. A pilot extraction of three studies will
be performed and the extraction reviewed by a third
author (KH) before continuing. At the completion of data
extraction, all extracted numeric data will be manually
re-checked against the original source by two authors
(KH and DZ), working independently. For additional
information on data extraction see Additional file 1.
Assessment of risk of bias
For randomised controlled trials, we will use the Cochrane
Collaboration’s tool for assessing the risk of bias in rando-
mised controlled trials [39]. Two review authors (SI and
DZ), working independently, will assess, for each outcome
within each study, the risk of bias as either ‘Low’, ‘High’
or ‘Unclear’ in each of the following domains: random
sequence generation, allocation concealment, blinding
of participants and personnel, blinding of outcome assess-
ment, incomplete outcome data and selective reporting.
Because we are analysing only the first period of any cross-
over studies, we will use the same method to assess these.
For quasi-randomised studies where sequence generation
and allocation concealment do not apply, we will use a
modified version of the tool that qualitatively compares
the baseline characteristics between intervention and
control groups. We will not perform risk of bias assess-
ment of commentaries, case reports or descriptive studies
included in respect of review Objective 2, assuming that
they are at high risk of bias. We will also assess other
potential sources of bias including baseline imbalances
and strategies for protection against contamination. InitialExclusion criteria
Children <18
Co-existing diagnosis of SB and AB (unlikely)
Known neurological or psychiatric comorbidities and/or a past history
of receiving biofeedback therapy for bruxism
Relaxation therapy not linked to bruxism specifically
Co-existing alternate therapy for bruxism in intervention group
(complex intervention)





Any other study design
.
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blinded assessment of five studies included in an existing
review of bruxism [40]. A third review author (KH) will
review the assessments and resolve any disagreements.Data analysis
Measures of treatment effect
We will examine the characteristics of included inter-
vention studies in order to determine the feasibility of
performing a meta-analysis. We will include all the studies
that meet our inclusion criteria and report the outcomes
of interest. All data will be partitioned for analysis accord-
ing to the underlying type of bruxism (SB and AB) and
nature of comparison (for example, versus placebo, versus
other treatment modality). Because we expect a range of
different techniques to be used to assess the continuous
quantitative outcomes included in the review we will use
the standard mean difference as the main measure of
treatment effect to both summarise individual study data
and pool for analysis. We will report dichotomous data
using odds ratios. In the event that some studies report
continuous data and some report dichotomised data, we
will not collapse continuous outcomes into dichotomous
outcomes. Instead, we will report these dichotomised data
separately (but not include them in any meta-analysis).
We will use a pre-defined significance level of 5% and
report values using 95% confidence intervals. We will
perform all statistical analyses using Review Manager
5 software (The Nordic Cochrane Centre, Copenhagen:
Denmark).Unit of analysis
The unit of analysis will be the patient. For studies
where only a proportion of the participants in a group
are eligible under our inclusion criteria, we will attempt
to obtain data for those participants only.Dealing with missing data
In the case of missing data we will first attempt to obtain
the missing information from the study authors. If this is
not possible we will perform an analysis of complete
cases but assume that the data are high risk of bias.Assessment of heterogeneity
We will use data extraction and tabulation to systematic-
ally characterise possible sources of clinical and methodo-
logical diversity and will use these characteristics to inform
a decision to undertake a pooled meta-analysis for each of
the planned subgroups. We will use the I2 statistic to assist
decision making (using the interpretation scheme provided
by the Cochrane collaboration [41]) but have chosen not
to set a fixed threshold for meta-analysis.Assessment of publication bias
We will characterise possible sources of reporting bias
on a per-study basis during quality assessment. If there are
at least 10 studies, we will use a funnel plot to explore
possible reporting bias at an aggregate level using visual
inspection.
Subgroups
A number of factors may influence the efficacy of biofeed-
back and, recognising this, we have pre-defined subgroups
into which data will be segregated, if possible, for analysis
of the primary outcome: (1) studies partitioned by type
of biofeedback according to the taxonomy generated
for the review (review Objective 1; for example, auditory,
vibratory, gustatory and CES); (2) studies partitioned by
duration of follow-up, grouped into short-, medium- and
longer-term follow-up (according to our prespecified cut-
offs for these periods); (3) participants with co-existing
bruxism-related morbidity (for example, TMD) versus those
without; and (4) studies partitioned into industry-funded
and non-industry-funded groups.
Meta-analysis and sensitivity analyses
If, after review, data demonstrate adequate homogeneity
we will generate a pooled effect estimate for each subgroup
for each outcome using a random effects meta-analysis
(DerSimonian-Laird method [42]). We will estimate an
effect pooled across subgroups only if it is meaningful
to do so after review of heterogeneity and other quality
issues, using a random-effects model.
Sensitivity analyses will be used to assess the robustness
of the findings in the case that: (1) one or more studies
contributing to the estimate presents a concern because
of possible biases, or other quality or conduct issues;
(2) one or more crossover trials are included in the syn-
thesis; (3) the form of the included biofeedback devices
has substantially changed because of technological advance-
ments (for example, miniaturized wearable devices versus
a bedside wired devices) which might affect outcomes like
acceptability; and (4) there are more than five studies in
the meta-analysis and either one or two studies account
for more than 50% of the weight.
Synthesis
We will use the PRISMA statement to structure the re-
porting of the systematic review [43]. We will generate an
initial narrative synthesis summarizing different types of
biofeedback available (review Objective 1) by devising and
refining a taxonomy to classify the form and content of
the included biofeedback interventions. Two authors (SI
and DZ), working independently, will come up with an
initial schema and this will be refined through discussion.
For those studies contributing to the outcomes assess-
ment (review Objective 2), we will present a narrative
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design, characteristics of participants, characteristics of
the interventions and outcomes. We will segregate the
information according to the type of bruxism and type of
biofeedback being reported, using the taxonomy developed
in the initial synthesis. We will also present a ‘Charac-
teristics of included studies’ table describing the methods,
participants, interventions and outcomes of individual
intervention studies. We will summarize the quantitative
effects for each outcome and the overall level of evidence
using a summary of findings table and the GRADE ap-
proach [44]. Finally, we will present a narrative account
highlighting the similarities and differences identified
between the two circadian variants of bruxism (review
Objective 3).
Discussion
No therapy to date has been shown to effectively and
permanently cure bruxism [2,8] and most accepted
approaches focus mainly on symptom management and
prevention of complications [2,8]. Biofeedback therapy
holds the potential for inducing long-term changes in
behaviour that could include reduction or elimination of
symptoms. However, it remains unclear whether biofeed-
back is an effective method for treatment of bruxism
[17]. Consequently, biofeedback has found limited use
in routine clinical practice [31]. The results of this system-
atic review will increase understanding of the scope for
biofeedback in the management of bruxism and identify
areas where further research is required.
Additional file
Additional file 1: Data that will be extracted from the studies.
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